Abstract
Background:
Patients with bone metastases secondary to prostate cancer are predisposed to skeletal-related events (SREs), including spinal cord compression, pathological fracture, surgery to bone and radiotherapy to bone. The objective of this study was to document current patterns of healthcare utilization and costs of SREs in patients with prostate cancer and bone metastases.
Methods:
This was a retrospective, observational study using the Thomson MedStat MarketScan Commercial Claims and Encounters database from September 2002 to June 2011. Study subjects included all persons with claims for prostate cancer and for bone metastases, and one or more claims for an SRE. Unique SRE episodes were identified based on a gap of at least 90 days without an SRE claim, and classified by treatment setting (inpatient or outpatient) and SRE type (spinal cord compression, pathological fracture, surgery to bone or radiotherapy).
Results:
Of 3919 patients with prostate cancer and bone metastases, 2090 (53%) had one or more SRE episodes. Among 1237 patients who met all other criteria, there were 1623 SRE episodes over a mean (s.d.) follow-up of 16.1 (12.9) months. The percent of episodes that required inpatient treatment ranged from 14% (radiotherapy) to 82% (surgery to bone). On average, inpatient episodes with surgery to bone (n=36 episodes) were most costly (mean (s.e.) $88 838 ($11 830)/episode), whereas outpatient episodes with surgery to bone (n=8 episodes) were least costly (mean (s.e.) $4749 ($1690)/episode). Of the total SRE costs (mean (s.e.) $20 984 ($951)/episode), 41% were attributable to outpatient radiotherapy (n=1169 episodes), 23% to inpatient radiotherapy (n=184 episodes), and 19% to inpatient treatment of pathological fractures (n=101 episodes).
Conclusions:
In patients with prostate cancer and bone metastases, SREs are associated with high costs and hospitalizations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
American Cancer Society. Detailed guide: prostate cancer what are the key statistics about prostate cancer? Available at http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/prostate-cancer-key-statistics. . Accessed 31 January 2012.
Coleman RE . Skeletal complications of malignancy. Cancer 1997; 80 (8 Suppl): 1588–1594.
Mundy GR . Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584–593.
Ohmori K, Matsui H, Yasuda T, Kanamori M, Yudoh K, Seto H et al. Evaluation of the prognosis of cancer patients with metastatic bone tumors based on serial bone scintigrams. Jpn J Clin Oncol 1997; 27: 263–267.
Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195–202.
Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813–822.
Coleman RE . Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165–176.
Oefelein MG, Ricchiuti V, Conrad W, Resnick MI . Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168: 1005–1007.
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879–882.
Barlev A, Song X, Ivanov B, Setty V, Chung K . Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 2010; 16: 693–702.
Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004; 67: 390–396.
Delea T, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006; 4: 341–347.
Delea TE, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol 2006; 1: 571–576.
Lage MJ, Barber BL, Harrison DJ, Jun S . The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008; 14: 317–322.
Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS . Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications. J Urol 2007; 178 (4 Pt 1): 1423–1428.
Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA . Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 2003; 43: 226–232.
McKiernan JM, Delea TE, Brandman J, Sung J, Raut M, Oster G . Effects of skeletal complications on total medical care costs in patients with bone metastases of solid tumors. American Society of Clinical Oncology 41st Annual Meeting, May 15, 2005 Orlando, FL (Poster). J Clin Oncol 2004 ASCO Annual Meeting Proceedings 2004; 22: 6057.
Hagiwara M, Oglesby A, Chung K, Zilber S, Delea TE . The impact of bone metastases and skeletal-related events on healthcare costs in prostate cancer patients receiving hormonal therapy. Community Oncol 2011; 8: 508–515.
Hornbrook MC, Hurtado AV, Johnson RE . Health care episodes: definition, measurement and use. Med Care Rev 1985; 42: 163–218.
Mehta SS, Suzuki S, Glick HA, Schulman KA . Determining an episode of care using claims data. Diabetic foot ulcer. Diabetes Care 1999; 22: 1110–1115.
Klinkman MS . Episodes of care for abdominal pain in a primary care practice. Arch Fam Med 1996; 5: 279–285.
Shekelle PG, Markovich M, Louie R . Comparing the costs between provider types of episodes of back pain care. Spine (Phila Pa 1976) 1995; 20: 221–226 ; discussion 227.
Deyo RA, Cherkin DC, Ciol MA . Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613–619.
Abrahm JL, Banffy MB, Harris MB . Spinal cord compression in patients with advanced metastatic cancer: ‘all I care about is walking and living my life’. JAMA 2008; 299: 937–946.
Conway R, Graham J, Kidd J, Levack P . What happens to people after malignant cord compression? Survival, function, quality of life, emotional well-being and place of care 1 month after diagnosis. Clin Oncol (R Coll Radiol) 2007; 19: 56–62.
Loblaw DA, Perry J, Chambers A, Laperriere NJ . Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol 2005; 23: 2028–2037.
Loblaw DA, Laperriere NJ . Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline. J Clin Oncol 1998; 16: 1613–1624.
Bureau of Labor Statistics. Consumer Price Index. Medical Care, US City Average. Series Id: CUUR0000SAM, CUUS0000SAM. US Department of Labor: Washington, DC, 2008; Available from URL http://www.bls.gov/cpi/home.htm.
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458–1468.
Acknowledgements
The paper was funded by Amgen.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
May Hagiwara, PhD and Thomas E Delea, MSIA are employees of Policy Analysis Inc. (PAI) and have received research funding and consulting fees from Amgen and Novartis. Karen Chung, PharmD, MS is an employee of and owns stock options in Amgen. M Wayne Saville, MD was an employee of and owned stock options in Amgen.
Additional information
Supplementary Information accompanies the paper on the Prostate Cancer and Prostatic Diseases website
Supplementary information
Rights and permissions
About this article
Cite this article
Hagiwara, M., Delea, T., Saville, M. et al. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis 16, 23–27 (2013). https://doi.org/10.1038/pcan.2012.42
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2012.42
Keywords
This article is cited by
-
Musculoskeletal oncology and thermal ablation: the current and emerging role of interventional radiology
Skeletal Radiology (2023)
-
Risk assessment of femoral pathological fracture in prostate cancer patients by computed tomography analysis
Journal of Bone and Mineral Metabolism (2022)
-
Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are naïve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events
The European Journal of Health Economics (2021)
-
Real-world safety and effectiveness of radium-223 in Japanese patients with castration-resistant prostate cancer (CRPC) and bone metastasis: exploratory analysis, based on the results of post-marketing surveillance, according to prior chemotherapy status and in patients without concomitant use of second-generation androgen-receptor axis-targeted agents
International Journal of Clinical Oncology (2021)
-
Double-plate compound osteosynthesis for pathological fractures of the proximal femur: high survivorship and low complication rate
Archives of Orthopaedic and Trauma Surgery (2020)